#Immunotherapy #Denmark #Copenhagen #HERVolution #Dr. Tine Gaziel

HERVolution Welcomes Dr. Tine Gaziel as Chief Medical Officer

In an exciting development for the biotechnology landscape, HERVolution Therapeutics ApS has appointed Dr. Tine Gaziel as their new Chief Medical Officer (CMO). This strategic move is expected to accelerate the company’s groundbreaking efforts in advancing dark genome-targeting immunotherapy for age-related diseases like cancer and metabolic disorders.

Who is Dr. Tine Gaziel?

Dr. Gaziel comes to HERVolution with a wealth of experience in clinical oncology and drug development. Holding an MD and a PhD focused on brain tumor models from the University of Copenhagen, she has more than two decades of expertise in both clinical and industrial settings. Her previous tenures include key roles at notable companies such as Eli Lilly, Y-mAbs Therapeutics, and Genmab, where she was instrumental in directing clinical development for pioneering early-phase immuno-oncology assets.

The Role of CMO at HERVolution

As CMO, Dr. Gaziel will oversee HERVolution’s regulatory and clinical development strategies. She is set to manage operations and program design as the company progresses its innovative pipeline of immune therapies targeting harmful antigens derived from the dark genome. Two lead therapies, IPT-001 and IPT-002, are currently making strides as promising HERV-targeted treatments geared towards addressing diseases typically associated with aging, such as metabolic conditions and cancer.

“Dr. Gaziel joins us with an impressive track record in early clinical development that will help us push our immune therapies toward clinical application,” said Dr. J. Robert Coleman, the CEO of HERVolution. He emphasized the company’s ambition to unlock the full therapeutic potential of human endogenous retroviruses (HERVs) to transform treatment paradigms for age-related diseases. Her expertise will be a significant asset in this journey as the company aims to advance its pipeline while maintaining patient safety at the forefront of their innovative practices.

Significance of HERV-Targeted Therapies

Understanding the potential of human endogenous retroviruses is crucial for advancing treatment options within the healthcare landscape. Dr. Gaziel expressed her enthusiasm for the timely and profound implications of this research. “There is an urgent need for effective treatments against cancers and age-related disorders. Our platform can empower the human immune system to target dark genome antigens effectively, representing a significant breakthrough in therapeutic possibilities,” she stated. This marks a notable shift in how such diseases may be treated in the near future, and she looks forward to collaborating with HERVolution’s team in bringing these novel therapies into clinical trials.

Progressing Towards Clinical Trials

HERVolution is actively engaged in cGMP manufacturing of its lead asset, IPT-001, with plans to initiate its clinical evaluation by early next year. The company's team remains committed to navigating the complexities of clinical trial processes efficiently while exploring the vast potential within the field of biotechnology.

A Bright Future for HERVolution

HERVolution Therapeutics, originally known as InProTher Aps, is paving the way in the biotechnology sector, specializing in developing immunotherapies targeting the dark genome. The company is poised to make significant contributions to the treatment of aging-related diseases with its innovative HERV-targeted therapies. Under Dr. Gaziel's leadership and expertise, the future looks promising for HERVolution as they embark on this mission to redefine treatment approaches for diseases of aging, reaffirming their commitment to scientific innovation and patient-centric solutions.